BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37968227)

  • 21. Whole-Body [
    Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
    Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Rohde M; Dyrvig AK; Johansen J; Sørensen JA; Gerke O; Nielsen AL; Høilund-Carlsen PF; Godballe C
    Eur J Cancer; 2014 Sep; 50(13):2271-9. PubMed ID: 25011659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of [
    Tovmassian D; Abdul Razak M; London K
    Int J Surg Oncol; 2016; 2016():6162182. PubMed ID: 28058117
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer.
    Zhang S; Li W; Liang F
    Oncotarget; 2016 Jul; 7(30):48600-48606. PubMed ID: 27203206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.
    Brenner W; Friedrich RE; Gawad KA; Hagel C; von Deimling A; de Wit M; Buchert R; Clausen M; Mautner VF
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):428-32. PubMed ID: 16404595
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Mirshahvalad SA; Metser U; Basso Dias A; Ortega C; Yeung J; Veit-Haibach P
    Radiology; 2023 Apr; 307(2):e221598. PubMed ID: 36692397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
    Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
    J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis.
    Martin E; Geitenbeek RTJ; Coert JH; Hanff DF; Graven LH; Grünhagen DJ; Verhoef C; Taal W
    Neuro Oncol; 2021 Apr; 23(4):557-571. PubMed ID: 33326583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.
    Moharir M; London K; Howman-Giles R; North K
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1309-17. PubMed ID: 20179923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic test accuracy of
    Seol HY; Kim YS; Kim SJ
    Clin Radiol; 2021 Nov; 76(11):863.e19-863.e25. PubMed ID: 34261597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.
    Brahmi M; Thiesse P; Ranchere D; Mognetti T; Pinson S; Renard C; Decouvelaere AV; Blay JY; Combemale P
    PLoS One; 2015; 10(10):e0138386. PubMed ID: 26445379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis.
    Liang X; Yu J; Wen B; Xie J; Cai Q; Yang Q
    Clin Radiol; 2017 Apr; 72(4):295-301. PubMed ID: 28139203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
    Lin CY; Lin CL; Kao CH
    Eur J Radiol; 2018 Oct; 107():158-165. PubMed ID: 30292261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The diagnostic performance of
    Samim M; Molenaar IQ; Seesing MFJ; van Rossum PSN; van den Bosch MAAJ; Ruers TJM; Borel Rinkes IHM; van Hillegersberg R; Lam MGEH; Verkooijen HM
    Surg Oncol; 2017 Mar; 26(1):37-45. PubMed ID: 28317583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.
    Yin Q; Xu H; Zhong Y; Ni J; Hu S
    BMC Cancer; 2022 Feb; 22(1):163. PubMed ID: 35148700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A two-way comparison of whole-body 18FDG PET-CT and whole-body contrast-enhanced MRI for distant metastasis staging in patients with malignant tumors: a meta-analysis of 13 prospective studies.
    Li J; Zhou H; Zhang X; Song F; Pang X; Wei Z
    Ann Palliat Med; 2020 Mar; 9(2):247-255. PubMed ID: 32233618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
    Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.